Meet Our Leadership Team
Our multi-disciplinary team of scientists, entrepreneurs, and technologists have united to create the future of precision neurology diagnostics. We are dedicated to building a next-generation digital biomarkers platform that could revolutionize the field.
Through the power of our proprietary machine-learning and augmented-reality technology, we are developing a precision neurology platform intended to redefine the industry standard. With our exceptional partner operations and platform delivery functions, we are continuously striving to redefine what it means to deliver a best-in-class service.
Our mission extends beyond simply offering solutions - we strive to make a transformative impact on healthcare within the field of neurological disease. By pushing the boundaries of what is possible, we hope to pave the way for a new era in healthcare and scale our industry-defining solutions to improve the lives of countless individuals, their families and healthcare providers.
CEO and Board Director
Marc is the Chief Executive Officer at Altoida. He is a healthcare technology business leader with more than 25 years of experience across both private and publicly-held companies. Prior to Altoida, Marc served as the Chief Operating Officer (COO) and Chief Financial Officer (CFO) of binx health, a digital health and molecular diagnostics company, where he co-founded binx's digital health business. At binx, he led the company through a critical phase of expansion from early to late-stage commercial product launch, generating multi-million revenue growth under his leadership. Marc also served as the COO and CFO of Good Start Genetics, which was acquired by Invitae (NVTA). As the inaugural CFO of T2 Biosystems (NASDAQ:TTOO), he played a fundamental role in navigating the company to a successful IPO. Marc was also CFO of Crashlytics, where he oversaw the company's acquisition by Twitter in 2013. Prior to Crashlytics, he was CFO of Ivenix (acquired by Fresenius), and also CFO of CHiL Semiconductor, which was acquired by International Rectifier (now Infineon). Prior to CHiL, Marc held roles of increasing responsibility at Picis Inc. He has raised hundreds of millions in capital and has delivered multiple M&A transactions providing value to shareholders. Marc serves on the Board of Directors of Altoida, Progentec Diagnostics and Pathfinder Health.
Mylea Charvat, Ph.D.
Chief Medical Officer
Mylea is the Chief Medical Officer at Altoida. A clinician with a business background, she was an early employee with Travelocity in the 1990s and a primary architect of the company’s award-winning customer success strategy. She left Travelocity after their 2001 IPO to pursue graduate work in clinical neuropsychology and neuroscience. She completed her PhD Fellowship at Stanford University School of Medicine and later founded the digital cognitive assessment company Savonix in 2014. As the Founder and CEO of Savonix Mylea steered the company through multiple rounds of venture funding, obtained FDA and PMDA clearance for their products and led her team in generating multi-million dollar revenue growth with customers such as MetLife, Bayer and Danone. Mylea has authored several peer review publications in mental health & neuroimaging. She has taught courses in medical ethics, biostatistics and research methods at Stanford School of Medicine, The University of San Francisco & San Francisco State University. She is a frequent contributor with Psychology Today, has written for Tech Crunch & Stat News & appeared as a subject matter expert at many conferences including AAIC, The Atlantic Council, the NIH & NIA & with the Duke Leadership Program.
Chief Financial Officer
Matt Gorman is a CFO for high growth companies in the life sciences. He is the Founder and Owner of CFgO, a finance, accounting, and strategy group supporting high growth companies. Working as a strategic partner with the CEO and management teams, Matt supports and guides companies through significant value inflection points including equity and debt financings, corporate partnering, IPO support, and M&A support. Matt has more than a decade of experience in leadership roles in the life sciences industry and previously worked for Fortune 50 and publicly traded companies. Matt is a certified public accountant and holds a B.A in accounting from Stonehill College and an M.B.A. from the University of Massachusetts Isenberg School of Management.
Ioannis Tarnanas, Ph.D.
Co-founder and Chief Scientific Officer
Ioannis is a co-founder and Chief Scientific Officer at Altoida. Ioannis’ research focuses on using new technologies to understand the aging process and to establish prevention methods that decrease the risk of developing dementia or delay the onset of the disease. Ioannis has developed models and screens of dementia using computerized tests of complex, real-life activities, such as a novel assessment of spatial navigation and movement trajectory. With this technology, Ioannis is developing a predictive tool based on cognitive and non-cognitive biomarkers of early onset dementia. At Altoida, Ioannis will pursue his development of computational biomarkers of Alzheimer’s disease. He is also working with local and international Alzheimer advocacy organizations to develop a responsible strategy to implement this technology and enable machine intelligence for disease prevention
VP, Software Product Development
Nivaldo is VP of Software Product Development at Altoida. He brings over 35 years’ experience in software engineering, including over 20 years in Healthcare Information Technology (HCIT). Nivaldo has led large, geographically distributed teams in the design and development of commercial HCIT platforms and products for hospitals across the globe, supporting solutions for Medication Management, electronic surveillance for Healthcare Associated Infections, Perioperative workflow, mobile point-of-care, health informatics using machine learning, and data / system integration. Nivaldo is an accomplished executive, adept at driving vision, strategy and execution of technological transformation in software organizations, having held leadership positions in product development and consulting services in startups and large enterprise settings across various industries covering public sector, telecommunications, and travel.
Board of Directors
Shayn is a Partner at Whitecap and joined the firm in 2015. Prior to joining Whitecap, Shayn was a lawyer at the corporate law firm Wildeboer Dellelce LLP. Shayn is active in the community, including involvement with Sunnybrook Health Sciences Centre and Sick Kids Hospital. Shayn holds a JD and an MBA from Queens University and a BA (Philosophy) from Western University.
Dr. Arnd Kaltofen
Arnd has collected a broad and long-standing experience in building and exiting ventures in the healthcare sector. He served as chairman and board director of companies such as Esbatech (acquired by Alcon), Kuros Biosurgery (reverse-IPO at SWX), Activaero (acquired by Vectura), or Ganymed Pharmaceuticals. In his previous career, he built a team dedicated to venture capital transactions in the healthcare industry for KPMG Corporate Finance. He gained his entrepreneurial experience in several Medical Device and Digital Health startups where he held various senior management positions in marketing, commercialization, and product development. As an MD he started his professional career in two university hospitals as an anaesthesiologist and in medical research. In addition to being an MD, Arnd also holds an MBA from the Kellogg Graduate Business School, USA, and WHU Koblenz, Germany, as well as a Postgraduate Degree in Computer Sciences from TU Munich, Germany.
Therese Maria Liechtenstein, PhD
Therese Maria (Thera) is an Investment Director in the Biotechnology team of M Ventures. Thera actively leads investments and represents M Ventures on the board of multiple portfolio companies. Previously Thera managed strategic projects for the Healthcare business of Merck and prior to this was a client relationship manager in the field of wealth preservation, at Industrie- & Finanzkontor Ets. She received her PhD in Immuno-Oncology from University College London, an MSc in Biomedical Sciences from the University of Amsterdam, and a BA in Biology and Business studies from New York University.
William Moffitt is an accomplished chief executive and board chairman with a proven track record of leading corporations --- of all market capitalizations, public and private --- in the rapid development of cutting-edge technologies and the commercialization of products and solutions that have helped shape the healthcare industry. From innovative, high-tech start-ups to larger more mature companies, Mr. Moffitt possesses demonstrated ability to attract and maintain Wall Street support at all stages of a company’s development. Until his retirement in early 2013, Mr. Moffitt was President, Chief Executive Officer and a director of Nanosphere, a developer, manufacturer and marketer of an advanced molecular diagnostic platform for the early detection of disease. Under his leadership Nanosphere transformed itself from a development stage company to a publicly listed commercialization company with a pipeline of products to drive continued growth and profitability. Prior to his tenure at Nanosphere, he was President, Chief Executive Officer and a director of i- STAT Corporation, a developer, manufacturer and marketer of diagnostic products that pioneered the point-of-care blood analysis market. Moffitt led i-STAT from its early research stage to commercialization and through its initial public offering to its premium acquisition by Abbott Laboratories in 2003. Prior to i-STAT Moffitt held executive positions at Baxter Healthcare Corporation, a manufacturer and distributor of health care products, and American Hospital Supply Corporation, a diversified manufacturer and distributor of health care products, which Baxter acquired in 1985. Moffitt has been a director and chairman of numerous private and public medical technology companies, commencing in the development stage progressing through to successful exits for many. Currently, Moffitt serves as chairman of Altoida, chairman of First Light Bioscience and chairman of Momentum BioScience, Ltd. Moffitt earned a B.S. from Duke University.